Health Affairs, 27, no. 1 (2008): w41-w51 (Published online 27 November 2007) doi: 10.1377/hlthaff.27.1.w41 © 2008 by Project HOPE	New Online   House Health Reform Bill   Paying for Reform   Vetting AHIP's Report   HIV/AIDS Costs   Brief: Insurance Reform   HA Blog Top 10

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Culliton, B. J. Search for Related Content PubMed PubMed Citation Articles by Culliton, B. J. Related Collections Research And Technology Consumer Issues

Web Exclusives

INTERVIEW

Insurers And ‘Targeted Biologics’ For Cancer: A Conversation With Lee N. Newcomer

New drugs for cancer, targeted at the specific genetic profile of various tumors, are revolutionizing cancer therapy, but at a very high cost. Most carry a price tag of $50,000 or more per patient per year. Lee Newcomer examines the medical and policy issues from his perspective at United Healthcare and from his experience as an oncologist. In this interview, Newcomer suggests that all patients receiving the targeted biologics be required to participate in a clinical trial or an insurance company registry so that data can be collected to assure that the right drugs are prescribed for the right patients.

                      What's this?

This article has been cited by other articles:

				P. B. Bach Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs N. Engl. J. Med., February 5, 2009; 360(6): 626 - 633. [Full Text] [PDF]

				K. A. Phillips Closing the Evidence Gap in the Use of Emerging Testing Technologies in Clinical Practice JAMA, December 3, 2008; 300(21): 2542 - 2544. [Full Text] [PDF]